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Brain renin–angiotensin system (RAS) is signiﬁcantly involved in the roles of the endocrine
RAS in cardiovascular regulation. Our studies indicate that the brain RAS participates in
the development of cardiac hypertrophy and ﬁbrosis through sympathetic activation. Inhi-
bition of sympathetic hyperactivity after myocardial infarction through suppression of the
brainRASappearsbeneﬁcial.Furthermore,thebrainRASmodulatesthecardiovascularand
ﬂuid–electrolyte homeostasis not only by interacting with the autonomic nervous system
but also by modulating hypothalamic–pituitary axis and vasopressin release.The brain RAS
is also involved in the modulation of circadian rhythms of arterial pressure, contributing
to non-dipping hypertension. We conclude that the brain RAS in pathophysiological states
interacts synergistically with the chronically overactive RAS through a positive biofeedback
in order to maintain a state of alert in diseased conditions, such as cardiac hypertrophy
and failure.Therefore, targeting brain RAS with drugs such as renin or angiotensin convert-
ing enzyme inhibitors or receptor blockers having increased brain penetrability could be of
advantage.
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According to the WHO report Global atlas on cardiovascular dis-
ease prevention and control,cardiovascular diseases are the leading
causes of death and disability in the world. Heart failure is a very
commonconditionthatiscostly,disabling,andpotentiallydeadly.
In developed countries, around 2% of adults suffer from heart
failure, but in those over the age of 65, this increases to 6–10%
(Dickstein et al., 2010). Conditions that damage or overwork the
heart muscle can cause heart failure. The most common causes
of heart failure are coronary heart disease (CHD), high blood
pressure, obesity, and diabetes (He et al., 2001). Treating these
problems can prevent or improve heart failure. Drugs acting on
the renin–angiotensin system (RAS),such as angiotensin convert-
ing enzyme (ACE) inhibitors or angiotensin receptor blockers are
ﬁrst-line therapy for all heart failure patients. Since the RAS has
bothendocrineandlocaltissuecomponents,RASdrugshavebeen
developed to attain increased tissue penetrability and volume of
distribution and consequently an efﬁcient inhibition/blockage of
both RAS components. Of the tissue systems, the brain RAS is
of particular interest for us. Accumulating evidence indicates that
angiotensins produced locally in various brain nuclei involved in
homeostasis control mainly in the hypothalamus and brain stem
interact with several neurotransmitter systems to regulate car-
diovascular and ﬂuid–electrolyte homeostasis, their biology and
mechanismsofactionrepresentinganactiveareaofactualresearch
interests (Baltatu et al., 2011; Diz et al., 2011). The brain RAS is
physicallyseparatedfromtheendocrineonebythepresenceof the
blood–brainbarrierwhichhampersthepenetrationofangiotensin
II (Ang II) from blood into the brain. Exceptions are some areas
lacking the blood–brain barrier through which circulating Ang II
can transmit its effects inside the brain. The brain RAS is involved
in the modulation of cardiovascular and ﬂuid–electrolyte home-
ostasis, complementing the classical roles of the endocrine RAS.
Several lines of evidence demonstrate that chronic over activation
of the brain RAS is responsible for the development and mainte-
nanceof hypertensioninseveralanimalmodelsof disease(Baltatu
et al.,2011; Diz et al., 2011).
To elucidate a contributory role of the brain RAS and its sig-
niﬁcance in diverse pathophysiological processes we developed
a transgenic rat [TGR(ASrAOGEN)] to inhibit the production
of angiotensinogen (AOGEN) speciﬁcally in the brain (Schinke
et al., 1999). The brain levels of AOGEN in TGR(ASrAOGEN)
rats are 90% low due to an antisense RNA expressed against
AOGEN, induced by means of the astrocyte-speciﬁc glial ﬁbril-
lary acidic protein promoter. As a consequence, these rats have
low blood pressure and a diabetes insipidus-like syndrome with
altered central vasopressinergic system (Campos et al., 2004).
The TGR(ASrAOGEN) rats were investigated in experimental
conditionsofhypertensionandheartpathology.Wedemonstrated
that the brain RAS signiﬁcantly contributes to the development of
hypertension in a transgenic model with overactive tissue RAS by
crossbreeding the TGR(ASrAOGEN) rats with the hypertensive
TGR(mREN2)27 strain (Schinke et al., 1999). We were further
interested to investigate whether the brain RAS is participating
in the development of hypertensive pathology in experimental
reno-vascular hypertension. Ang II when infused at doses of 50–
250ng/kg/minsubcutaneously,whichdonotproducedirectvaso-
constriction are described as “subpressor” or “slow-pressor” and
caninduceagradualincreaseof bloodpressureindaystoweeks.It
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representsamodelof reno-vascularhypertensionwithlowplasma
reninactivity(PRA).ThesubpressorAngII-inducedhypertension
at TGR(ASrAOGEN) rats was signiﬁcantly attenuated supporting
the importance of the brain RAS in this process (Baltatu et al.,
2000). Furthermore, the Ang II-induced cardiac hypertrophy and
ﬁbrosis was considerably attenuated as well. This attenuation of
thecardiacphenotypeinthismodelof experimentalhypertension
might not only be due to the reduction of blood pressure but also
because of a disturbed autonomic nervous system.
Several authors presented ﬁndings indicating thatAng II inter-
actswiththeautonomicnervoussystematseverallevels,namelyat
postganglionic nerve terminals, sympathetic ganglia, and within
the central nervous system (reviewed in Bader et al., 2001). Ang
II signaling in the brain modulates reﬂex control of heart rate
and sympathetic outﬂow (Dampney et al., 2007; Carlson and
Wyss, 2008). Studies from our group provide evidence that a
permanent inhibition of brain RAS may cause a decreased basal
sympatheticoutﬂow,asithasbeenobservedinTGR(ASrAOGEN)
rats (Campos et al., 2006a; Parrish et al., 2008). Power spectral
analysis of heart rate and blood pressure indicates an altered
autonomic nervous system activity with a dominance of vagal
tone over sympathetic tone and exaggerated spontaneous barore-
ﬂex sensitivity (Baltatu et al., 2001). As a consequence to a
diminished basal activity of sympathetic nervous system, the
hearts of TGR(ASrAOGEN) exhibit an increased sensitivity to
β-receptor agonists (Campos et al.,2006a; Parrish et al.,2008).
The brain RAS – sympathetic nervous system connection is
importantinthedevelopmentof leftventriculardysfunctionafter
myocardial infarction (Huang and Leenen, 2009). Sympathetic
activity surges in parallel with the progress of damage in cardiac
performance, contributing to the progression of the heart failure
(Packer,1992).TGR(ASrAOGEN)ratsexhibitmarkedattenuation
of both sympathetic hyperactivity and of left ventricular remod-
eling and dysfunction after myocardial infarction (Wang et al.,
2004). As a consequence of a lower post-infarct sympathetic acti-
vation in the TGR(ASrAOGEN) rats,there was a blunted increase
in tyrosine hydroxylase (TH; the rate-limiting enzyme in norepi-
nephrine synthesis; Parrish et al., 2008). Lower cardiac TH levels
mayrepresentamechanismcontributingtothelowerpathological
elevation of norepinephrine.
Not only does peripheral Ang II interact with the brain RAS
to activate the sympathetic nervous system in chronically overac-
tive conditions, but also the brain RAS appear to inﬂuence renal
renin release. The sympathetic nervous system, which is involved
in the ﬁght-or-ﬂight reaction, is one of the main stimulators of
renal renin release. During the stress reaction, there is an increase
FIGURE 1 | (A) Effect of Ang II infusion (100ng/kg/min s.c.) on systolic arterial
pressure (SAP). Data are extracted from telemetry recording and data
acquisition as day mean.The start of Ang II infusion is at the end of day 0. LE
indicates Long–Evans rats (n=6); Brattleboro rats (n=6). (B). Increase of
systolic BP after Ang II infusion calculated by subtracting the 2-day mean
basal values from the mean values of the last 2days at the end of Ang II
infusion [mean day (5, 6) – mean day (−1, 0)] (Long–Evans rats, n=6;
Brattleboro rats, n=6). Data are expressed as mean±SE.
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in blood levels of renin in addition to epinephrine. We provided
evidence that brain RAS is an important player involved in the
stress-induced renin release. The TGR(ASrAOGEN) rats with low
brain AOGEN exposed to stress have elevations of only 50% on
PRAlevels(markerof bothrenalreninreleaseandof thereactivity
to different types of stressors) from those of the stressed control
rats (Baltatu et al., 2004). Therefore, inhibition of the brain RAS
mayrepresentaprotectivestrategyagainstchronicandgeneralized
activation of both endocrine and local systems in disease.
Brain RAS modulates the cardiovascular and ﬂuid–electrolyte
homeostasis not only by interacting with the autonomic
nervous system but also by modulating hypothalamic–pituitary
axis and vasopressin release (Baltatu et al., 2004). Since the
angiotensinogen-deﬁcient TGR(ASrAOGEN) rats have lower
plasma levels of vasopressin and an altered central vasopressin-
ergic system (Schinke et al., 1999; Campos et al., 2004), we
considered that this might be also one mechanism contribut-
ing to the attenuated Ang II-induced hypertension and cardiac
hypertrophy. Therefore, we studied the Ang II-induced hyper-
tension in vasopressin-deﬁcient Brattleboro rats, as well. Basal
systolic arterial pressure (SAP) monitored by telemetry was
signiﬁcantly lower in Brattleboro rats as in TGR(ASrAOGEN)
in comparison with the respective parent strain Long–Evans
(LE) rats (119.4±1.1 vs. 129.4±1.4mmHg, p <0.001, respec-
tively)orSprague-Dawley(SD;122.5±1.5vs.128.9±1.9mmHg,
p <0.05, respectively). The increase in SAP induced by 7days
of chronic Ang II infusion (100ng/kg/min) in Brattleboro rats
was similar to the LE rats (Figure 1; delta SAP: 25.1±4.8 vs.
18.2±7.7mmHg,p >0.05,respectively),incontrasttothesignif-
icantly attenuated hypertension in TGR(ASrAOGEN; delta SAP:
29.8±4.2 vs. 46.3±2.5mmHg, p <0.005 vs. control SD rats).
Heart hypertrophy measured as heart weight per body weight was
evident neither in LE nor in Brattleboro rats, probably due to the
mild hypertension levels. These results together with our previ-
ous results (Baltatu et al., 2000) indicate that the brain RAS but
not vasopressin system plays an important role in mediating the
hypertension induced by slow-pressor doses of Ang II.
Circadian variability of blood pressure may constitute another
mechanism through which brain RAS may participate to the
hypertensive target organ injury and cardiovascular events.
According to the Seventh Report of the Joint National Com-
mittee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (JNC7), ambulatory blood pressure moni-
toring is warranted for evaluation of “white-coat” hypertension
in the absence of target organ injury (Chobanian et al., 2003).
It is also helpful to assess patients with apparent drug resis-
tance, hypotensive symptoms with antihypertensive medications,
episodic hypertension,and autonomic dysfunction. In most indi-
viduals,BP decreases by 10–20% during the night; those in whom
such reductions are not present are at higher risk for cardiovascu-
larevents.A“non-dipping”bloodpressure(reversednighttimeBP
dipping pattern) was associated with a 2.2-fold higher incidence
of heart failure (Ingelsson et al., 2006). Our group was the ﬁrst
to determine that slow-pressor Ang II infusion may induce a shift
in BP circadian rhythm, making it a convenient and reproducible
experimentalmodelof AngII-inducednon-dippinghypertension
(Baltatu et al., 2001). These alterations in BP circadian rhythm
are not synchronized with alterations of heart rate or locomotor
activity, contributing to the concept that the circadian variability
of blood pressure and heart rate are differentially regulated (Bal-
tatu et al., 2001; Campos et al., 2006b). The brain RAS appears
to be also an important modulator of the circadian BP rhythm
FIGURE2|B r a i nR A Si npathophysiological states interacts synergistically with the chronically overactive RAS through a positive biofeedback in
order to maintain a state of alert diseased conditions, such as cardiac hypertrophy and failure.
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(Baltatu et al.,2001;Camposetal.,2006b).AngIInotonlyinduces
alterations in the circadian rhythm of BP but also its local pro-
duction in the brain modulates the synthesis of both melatonin
and vasopressin, which are important hormones regulating cir-
cadian rhythms (Baltatu et al., 2002; Campos et al., 2002, 2004).
Furthermore,melatonin itself may alter the short-term variability
of cardiovascular parameters, including the baroreﬂex (Campos-
Santos et al., 2000). With these studies we demonstrated that the
brain RAS is an important regulator of circadian rhythm of blood
pressure. The experimental model of Ang II-induced hyperten-
sion might be useful to further dissect the pathophysiology and
molecular biology of non-dipping hypertension.
In summary, several lines of evidence indicate that the brain
RAS is involved in cardiovascular diseases including heart failure
contributing to pathophysiological alterations (Figure2). Chron-
ically overactive RAS is thus recruiting tissue RASs through a
positive biofeedback in order to maintain a state of alert diseased
conditions. A circadian pattern becomes quite obvious in the
occurrence of acute cardiovascular diseases, such as ischemia,
infarction, stroke, and sudden death, and new chronotherapeu-
tic approaches in antihypertensive therapy are trying to exploit
the knowledge of circadian rhythms in order to reduce these
events. Therefore, targeting brain RAS with drugs such as renin
or ACE inhibitors or receptor blockers having increased brain
penetrability could be of beneﬁt. These RAS-targeting drugs are
ﬁrst-line therapy for all heart failure patients. Since the RAS has
both endocrine and local tissue components,RAS drugs are being
developed to attain increased tissue penetrability and volume of
distribution and consequently an efﬁcient inhibition of both RAS
components.
ACKNOWLEDGMENTS
The work of the authors was supported by the Deutsche Forschun
gsgemeinschaft (BA1374/13-2, BA1374/16-1, and BA1374/20-1).
REFERENCES
Bader, M., Peters, J., Baltatu, O., Muller,
D. N., Luft, F. C., and Ganten,
D. (2001). Tissue renin-angiotensin
systems: new insights from exper-
imental animal models in hyper-
tension research. J. Mol. Med. 79,
76–102.
Baltatu, O., Afeche, S. C., Jose dos
Santos, S. H., Campos, L. A., Bar-
bosa, R., Michelini, L. C., Bader, M.,
and Cipolla-Neto, J. (2002). Locally
synthesized angiotensin modulates
pinealmelatoningeneration.J.Neu-
rochem. 80, 328–334.
Baltatu, O., Campos, L. A., and Bader,
M. (2004). Genetic targeting of the
brain renin-angiotensin system in
transgenic rats: impact on stress-
induced renin release. Acta Physiol.
Scand. 181, 579–584.
Baltatu, O., Janssen, B. J., Bricca, G.,
Plehm, R., Monti, J., Ganten, D.,
and Bader, M. (2001). Alterations
in blood pressure and heart rate
variability in transgenic rats with
low brain angiotensinogen. Hyper-
tension 37, 408–413.
Baltatu, O., Silva, J. A. Jr., Gan-
ten, D., and Bader, M. (2000).
The brain renin-angiotensin system
modulates angiotensin II-induced
hypertension and cardiac hypertro-
phy. Hypertension 35, 409–412.
Baltatu,O.C.,Campos,L.A.,andBader,
M. (2011). Local renin-angiotensin
s y s t e ma n dt h eb r a i n–ac o n t i n u -
ousquestforknowledge.Peptides 32,
1083–1086.
Campos, L. A., Afeche, S. C., Plehm,
R., Michelini, L. C., Cipolla-Neto, J.,
Baltatu, O., and Bader, M. (2002).
Altered circadian rhythm reentrain-
ment and pineal indoles in rats with
lowbrainangiotensinogen.J.Hyper-
tens. 20, P1086.
Campos, L. A., Couto, A. S., Iliescu,
R., Santos, J. A., Santos, R. A., San-
tos, R. A., Ganten, D., Campagnole-
Santos, M. J., Bader, M., and Bal-
tatu, O. (2004). Differential regula-
tion of central vasopressin receptors
in transgenic rats with low brain
angiotensinogen. Regul. Pept. 119,
177–182.
Campos, L. A., Iliescu, R., Fontes, M.
A., Schlegel, W. P., Bader, M., and
Baltatu, O. C. (2006a). Enhanced
isoproterenol-induced cardiac
hypertrophy in transgenic rats with
low brain angiotensinogen. Am. J.
Physiol. Heart Circ. Physiol. 291,
H2371–H2376.
Campos, L. A., Plehm, R., Cipolla-
Neto, J., Bader, M., and Baltatu,
O. C. (2006b). Altered circadian
rhythmreentrainmenttolightphase
shifts in rats with low levels of
brain angiotensinogen. A m .J .P h y s -
iol. Regul. Integr. Comp. Physiol. 290,
R1122–R1127.
Campos-Santos, L., Cipolla-Neto, J.,
and Michelini, L. (2000). Beneﬁcial
effect of melatonin on baroreceptor
reﬂexcontrolof heartrateisblocked
in spontaneously hypertensive rats.
J. Hypertens. 18, S95–S95.
Carlson, S. H., and Wyss, J. M. (2008).
Neurohormonal regulation of the
sympathetic nervous system: new
insights into central mechanisms of
action. Curr. Hypertens. Rep. 10,
233–240.
Chobanian, A. V., Bakris, G. L., Black,
H. R.,Cushman,W. C.,Green,L. A.,
Izzo, J. L. Jr., Jones, D. W., Mater-
son, B. J., Oparil, S., Wright, J. T.
Jr., Roccella, E. J., Joint National
Committee on Prevention, Detec-
tion, Evaluation, and Treatment of
High Blood Pressure, and National
Heart, Lung, and Blood Institute,
National High Blood Pressure Edu-
cation Program Coordinating Com-
mittee.(2003).Seventhreportof the
Joint National Committee on Pre-
vention, Detection, Evaluation, and
Treatment of High Blood Pressure.
Hypertension 42, 1206–1252.
Dampney, R. A., Tan, P. S., Sheriff,
M. J., Fontes, M. A., and Horiuchi,
J. (2007). Cardiovascular effects of
angiotensin II in the rostral ven-
trolateral medulla: the push-pull
hypothesis. Curr. Hypertens. Rep. 9,
222–227.
Dickstein, K., Vardas, P. E., Auric-
chio, A., Daubert, J. C., Linde, C.,
McMurray, J., Ponikowski, P., Pri-
ori, S. G., Sutton, R., van Veld-
huisen, D. J., ESC Committee for
Practice Guidelines (CPG), Vahan-
ian,A.,Auricchio,A.,Bax,J.,Ceconi,
C., Dean, V., Filippatos, G., Funck-
Brentano, C., Hobbs, R., Kearney,
P., McDonagh, T., Popescu, B. A.,
Reiner, Z., Sechtem, U., Sirnes, P. A.,
Tendera, M., Vardas, P., Widimsky,
P., Document Reviewers, Tendera,
M., Anker, S. D., Blanc, J. J., Gas-
parini,M.,Hoes,A.W.,Israel,C.W.,
Kalarus, Z., Merkely, B., Swedberg,
K., and Camm, A. J. (2010). 2010
Focused Update of ESC Guidelines
on device therapy in heart failure:
an update of the 2008 ESC Guide-
lines for the diagnosis and treat-
ment of acute and chronic heart
failure and the 2007 ESC guidelines
for cardiac and resynchronization
therapy. Developed with the special
contribution of the Heart Failure
Association and the European Heart
RhythmAssociation.Eur.HeartJ.31,
2677–2687.
Diz, D. I., Arnold, A. C., Nautiyal, M.,
Isa,K.,Shaltout,H.A.,andTallant,E.
A. (2011). Angiotensin peptides and
central autonomic regulation. Curr.
Opin. Pharmacol. 11, 131–137.
He,J.,Ogden,L.G.,Bazzano,L.A.,Vup-
puturi, S., Loria, C., and Whelton,
P. K. (2001). Risk factors for con-
gestive heart failure in US men and
women: NHANES I epidemiologic
follow-up study. Arch. Intern. Med.
161, 996–1002.
Huang, B. S., and Leenen, F. H. (2009).
The brain renin-angiotensin-
aldosterone system: a major
mechanism for sympathetic
hyperactivity and left ventricular
remodeling and dysfunction after
myocardial infarction. Curr. Heart
Fail Rep. 6, 81–88.
Ingelsson, E., Bjorklund-Bodegard, K.,
Lind, L., Arnlov, J., and Sundstrom,
J. (2006). Diurnal blood pressure
pattern and risk of congestive heart
failure. JAMA 295, 2859–2866.
Packer, M. (1992). The neurohormonal
hypothesis: a theory to explain the
mechanismofdiseaseprogressionin
heart failure.J.Am. Coll. Cardiol. 20,
248–254.
Parrish, D. C., Gritman, K., Van Win-
kle, D. M., Woodward, W. R., Bader,
M., and Habecker, B. A. (2008).
Postinfarct sympathetic hyperactiv-
ity differentially stimulates expres-
sion of tyrosine hydroxylase and
norepinephrine transporter. Am. J.
Physiol. Heart Circ. Physiol. 294,
H99–H106.
Schinke, M., Baltatu, O., Bohm, M.,
Peters, J., Rascher, W., Bricca, G.,
Lippoldt, A., Ganten, D., and Bader,
M.(1999).Bloodpressurereduction
and diabetes insipidus in transgenic
rats deﬁcient in brain angiotensino-
gen. Proc. Natl. Acad. Sci. U.S.A. 96,
3975–3980.
Wang, H., Huang, B. S., Ganten,
D., and Leenen, F. H. (2004).
Frontiers in Physiology | Integrative Physiology January 2012 | Volume 2 | Article 115 | 4Campos et al. Brain RAS and the heart
Prevention of sympathetic and car-
diac dysfunction after myocardial
infarctionintransgenicratsdeﬁcient
in brain angiotensinogen. Circ. Res.
94, 843.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 06 October 2011; accepted: 14
December2011;publishedonline:03Jan-
uary 2012.
Citation: Campos LA,Bader M and Bal-
tatu OC (2012) Brain renin–angiotensin
system in hypertension, cardiac hyper-
trophy, and heart failure. Front. Physio.
2:115. doi: 10.3389/fphys.2011.00115
This article was submitted to Frontiers
in Integrative Physiology, a specialty of
Frontiers in Physiology.
Copyright © 2012 Campos, Bader and
Baltatu. This is an open-access article
distributed under the terms of the Cre-
ative Commons Attribution Non Com-
mercial License, which permits non-
commercial use, distribution, and repro-
duction in other forums, provided the
original authors and source are credited.
www.frontiersin.org January 2012 | Volume 2 | Article 115 | 5